Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joerg Thomas

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
Ejhaem|February 23, 2023
Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cellsMaximilian Kiefer, Lorenz Thurner, Theresa Bock, et al.
Annals of Hematology|August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysisLuca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Task2 potassium channels set central respiratory CO2 and O2 sensitivityChristian Gestreau, Dirk Heitzmann, Joerg Thomas, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieSalah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, et al.
Immunology Letters|September 12, 2024
Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritisMarie-Christin Hoffmann, Natalie Fadle, Evi Regitz, et al.
European Journal of Immunology|March 31, 2021
Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patientsIgor Kos, Benedikt Balensiefer, Vadim Lesan, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cancer Immunology, Immunotherapy : CII|April 18, 2020
Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potentialMoritz Bewarder, Gerhard Held, Lorenz Thurner, et al.
Ejhaem|February 23, 2023
Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cellsMaximilian Kiefer, Lorenz Thurner, Theresa Bock, et al.
Annals of Hematology|August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysisLuca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.
Leukemia & Lymphoma|October 20, 2021
Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.
Hemasphere|July 15, 2021
The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma CellsMoritz Bewarder, Maximilian Kiefer, Helene Will, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Task2 potassium channels set central respiratory CO2 and O2 sensitivityChristian Gestreau, Dirk Heitzmann, Joerg Thomas, et al.
The Lancet. Oncology|September 23, 2011
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesPatrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 20, 2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische OnkologieSalah-Eddin Al-Batran, Joerg Thomas Hartmann, Stephan Probst, et al.
Immunology Letters|September 12, 2024
Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritisMarie-Christin Hoffmann, Natalie Fadle, Evi Regitz, et al.
European Journal of Immunology|March 31, 2021
Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patientsIgor Kos, Benedikt Balensiefer, Vadim Lesan, et al.
Pageof 5